tirzepatide cease and desist Novo Nordisk, Eli Lilly Sending Cease-and-Desist Letters Over Compounded Semaglutide Eli Lilly strikes Zepbound deal

In its initial announcements, CMS indicated that the GLP-1 Bridge program would run from July 1, 2026, through the end of the year, with the BALANCE Model beginning in January 2027

Orforglipron also is more likely to increase heart rate (by about 4 beats per minute)

This information can be particularly valuable when a patient has tried other weight loss approaches without sustained success, or when rapid metabolic changes are observed

Holman N, Knighton P, Kar P, O'Keefe J, Curley M, Weaver A, Barron E, Bakhai C, Khunti K, Wareham NJ, Sattar N (2020) Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study